All In Biotech

Drug Trial Radar · NCT03114319

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

An Open-label, Multi-center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

227

Actual

Start

May 26, 2017

Primary completion

Jul 4, 2025

Study completion Jul 4, 2025

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 14, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this first in human (FIH) trial was to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in adult patients with advanced solid tumors in selected indications.

Conditions

  • Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC)
  • KRAS G12-mutant NSCLC
  • Esophageal Squamous Cell Cancer (SCC)
  • Head/Neck SCC
  • Melanoma
  • Advanced Gastrointestinal Stromal Tumors (GIST)
  • Advanced NRAS/BRAFT wt Cutaneous Melanoma

Interventions

  • TNO155Drug

    TNO155 for oral administration

  • TNO155 in combination with EGF816 (nazartinib)Drug

    TNO155 for oral administration; EGF816 (nazartinib) for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events and serious adverse eventsTime frame: up to 5 years; at least once per treatment cycle
  2. Number of participants with dose limiting toxicitiesTime frame: up to 28-day cycle
  3. Number of participants with dose interruptions and reductionsTime frame: Up to 5 years
  4. Dose intensity of study drugsTime frame: Up to 5 years

Locations

18 sites in 9 countries. Site status is shown where the registry gives one.

  • H Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Dana Farber Cancer Center

    Boston, Massachusetts

  • Memorial Sloane Ketterin Cancer Ctr

    New York, New York

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Kobe, Japan

  • Novartis Investigative Site

    Amsterdam, Netherlands

  • Novartis Investigative Site

    Rotterdam, South Holland, Netherlands

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Barcelona, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.